ORL Kids Mouthwash, Bubblegum Flavor, 16.9 oz. (500ml) per bottle, ORL Labs, LLC, Scottsdale, Arizona USA
Published January 14, 2026 · Recall initiated: December 8, 2025
Summary
FDA records drug Class II recall D-0252-2026, published January 14, 2026 and initiated December 8, 2025. Recalling firm: Signature Formulations, LLC; Status: Ongoing; Reported quantity: 570 bottles; Lot: Lot #: 250505P9, Exp. Date 05/27. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
cGMP Deviations
What to do
Voluntary: Firm initiated · E-Mail
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Signature Formulations, LLC
- Distributor
- AZ only
- Lot
- Lot #: 250505P9, Exp. Date 05/27
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAORL Kids Natural Toothpaste, Bubblegum Flavor, 4 oz (120ml), ORL Labs, LLC, Scottsdale, Arizona USAJanuary 14, 2026
- FDATri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, ImprimisJanuary 14, 2026
- FDADexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection,January 14, 2026
- FDAOxycodone and Acetaminophen CII Tablets USP, 10mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves, MOJanuary 14, 2026
- FDADexamethasone Moxifloxacin, 1 mg/mL and 5 mg/mL, 1 mL Intraocular Injection, Rx only, Imprimis NJOF, LLC,January 14, 2026
- FDAOxycodone and Acetaminophen CII Tablets USP, 7.5 mg/325 mg, 100 tablets, Rx only, SpecGx LLC, Webster Groves,January 14, 2026
Questions about this recall
Was ORL Kids Mouthwash, Bubblegum Flavor, 16.9 oz. (500ml) per bottle, ORL Labs, LLC, Scottsdale, Arizona USA recalled?
Yes. FDA published recall D-0252-2026 on January 14, 2026. Reported hazard: cGMP Deviations
What should I do if I have this product?
Voluntary: Firm initiated · E-Mail